Announced Mon, 29 Jun · 22:51 IST
Biocon makes BBL wholly-owned subsidiary via share swap
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+0.9%1-day move
₹414.20
prior close
₹416.15
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.9-0.8-0.7-0.8+0.9+1.2+3.3+2.4-2.0-1.9+6.4———
Up moveDown movePending
AI summary
Biocon acquired 1,15,36,956 equity shares of Biocon Biologics Limited (BBL) from 127 selling shareholders, making BBL a wholly-owned subsidiary. As consideration, Biocon allotted 87,86,362 equity shares at Rs. 376.41 per share on a preferential basis. Paid-up share capital rose from Rs. 8,10,45,38,865 to Rs. 8,14,84,70,675. This follows shareholder approval via postal ballot on June 7, 2026.
Likely market impact
Mild dilution for existing shareholders as Biocon gains full control of its biologics arm with no cash outflow, simplifying group structure.